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Conventional drug delivery systems have little 
control over their drug release and almost no control 
over the effective concentration at the target site. 
This kind of dosing pattern may result in constantly 
changing, unpredictable plasma concentrations. 
Drugs can be delivered in a controlled pattern over a 
long period of time by the process of osmosis. 
Osmotic devices are the most promising strategy 
based systems for controlled drug delivery. They are 
the most reliable controlled drug delivery systems 
and could be employed as oral drug delivery 
systems. The present review is concerned with the 
study of drug release systems which are tablets 
coated with walls of controlled porosity. When these 
systems are exposed to water, low levels of water 
soluble additive is leached from polymeric material 
i.e. semipermeable membrane and drug releases in a 
controlled manner over an extended period of time. 
Drug delivery from this system is not influenced by 
the different physiological factors within the gut 
lumen and the release characteristics can be 
predicted easily from the known properties of the 
drug and the dosage form. In this paper, various 
types of osmotically controlled drug delivery 
systems and the basic components of controlled 
porosity osmotic pump tablets have been discussed 
briefly. 
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Osmotically Controlled Drug Delivery System 
(OCDDS) 
 
Osmotic devices are the most reliable 
controlled drug delivery systems (CDDS) and can 
be employed as oral drug delivery systems. Osmotic 
pressure is used as the driving force for these 
systems to release the drug in a controlled manner.  
Osmotic pump tablet (OPT) generally consists of a 
core including the drug, an osmotic agent, other 
excipients and semipermeable membrane coat [1]. 
The design, mechanism and uses of various types of 
osmotic systems are shown in table 1 [2].   In this 
study mainly the basic components of controlled 




 Easy to formulate and simple in operation. 
 
 Improve patient compliance with reduced 
frequency. 
 





 Dose dumping  
 
 Rapid development of tolerance 
 
 
 Retrieval therapy is not possible in the 
case of unexpected adverse events 
 
 
Types of Osmotically controlled drug delivery 
systems: 
 
 Elementary osmotic pump 
 
 Multi chambered osmotic pumps  
 
 
 Push-pull osmotic pumps 
 





 Miscellaneous types 
 
 Controlled-porosity osmotic pumps 
 
 
 Modified osmotic pumps for insoluble 
drugs 
 
 Multi particulate delayed release systems 
 
 





































Single chamber osmotic pumps  
Elementary Osmotic 
Pump (EOP)  




with delivery orifice  
The water penetrates inside the dosage 
form. This results in formation of 
saturated solution of drug within the 
core, which is dispensed at a controlled 
rate from the delivery orifice present in 
the membrane.  
 Moderately  soluble API 
  
 60- 80% constant  release   
 
Controlled-porosity 
osmotic pump (CPOP) 





soluble additives  
Delivery orifice is formed by the 
incorporation of a leachable 
component. Once the tablet comes in 
contact with aqueous environment, 
Water-soluble additives dissolve lead 
to the formation of a microporous 
membrane. Water diffuses into the core 
through the microporous membrane, 
creating an osmotic gradient and 
thereby controlling the release of drug. 
 Poorly soluble    drugs 
 
Multi-chamber osmotic pumps 
Push-pull osmotic pump 
(PPOP)  
Core Tablet:  
Layer 1:  API ± 
osmogents  
Layer 2: Polymeric 
osmotic agents  
Coat: Semi 
permeable membrane 
with delivery orifice  
After coming in contact with the 
aqueous environment, polymeric 
osmotic layer swells and pushes the 
drug layer, and thus releasing drug in 
the form of fine dispersion through the 
orifice.  
 For delivery of  APIs 
having  extremes of water 
 solubility  
 Modifications can  be 
done:  
- delayed push-pull  
- multi-layer push-   pull  
- push-stick system  
 
Sandwiched Osmotic 
tablets (SOTS)  
Core tablet: 3 layers  
Middle layer: push 
layer  
2 attached layers: API  
Coat: Semi 
permeable membrane 
with two side 
delivery orifice  
The middle push layer swells and drug 
is released from delivery orifices 
present on two sides of the tablet.  
 API release from  two 


















Table.2 Osmotic pressures of saturated solution of commonly used osmogents [15] 
 





Sodium chloride 356 
Fructose 335 
Lactose-Sucrose 250 








Potassium sulphate 39 
Mannitol 38 
Sodium phosphate tribasic. 12H2O 36 
Sodium phosphate dibasic. 7 H2O 31 
Sodium phosphate dibasic. 12 H2O 31 
Sodium phosphate monobasic. H2O 28 























Controlled-Porosity Osmotic Pump (CPOP) 
 
The controlled-porosity osmotic pump 
tablet concept was developed as an oral drug 
delivery system by Zentner et al (1985, 1991), 
Zentner and Rork (1990), Appel and Zentner 
(1991), and Mc Celland et al. (1991). The 
controlled-porosity osmotic pump tablet (CPOP) is 
a spray-coated or coated tablet with a 
semipermeable membrane (SPM) containing 
leachable pore forming agents. They do not have 
any aperture to release the drugs; drug release is 
achieved through the pores, which are formed in the 
semipermeable wall in situ during the operation. In 
this system, the drug, after dissolution inside the 
core, is released from the osmotic pump tablet by 
hydrostatic pressure and diffusion through pores 
created by the dissolution of pore formers 
incorporated in the membrane (Fig. 1). The 
hydrostatic pressure is created either by an osmotic 
agent or by the drug itself or by a tablet component, 
after water is imbibed across the semipermeable 
membrane.  
 
This membrane after formation of pores 
becomes permeable for both water and solutes. A 
controlled-porosity osmotic wall can be described as 
having a sponge like appearance. The pores can be 
continuous that have micro porous lamina, 
interconnected through tortuous paths of regular and 
irregular shapes. Generally, materials (in a 
concentration range of 5% to 95%) producing pores 













This system is generally applicable for 
only water-soluble drugs as poorly water soluble 
drugs cannot dissolve adequately in the volume of 
water drawn into the OPT. Recently this problem 
was overcome by adding agents like sulfobutyl 
ether- -cyclodextrin (SBE)7m- -CD or  
hydroxypropyl- -cyclodextrin (HP- -CD) as  
solubilizing and osmotic agents. Several approaches 
have been developed to prepare the porous 
membrane by spray coating using polymer solutions 
containing dissolved or suspended water-soluble 
materials. The rate of drug release can also be varied 
by having different amounts of osmogents in the 
system to form different concentrations of 
channeling agents for delivery of the drug from the 
device. Incorporation of the cyclodextrin-drug 
complex has also been used as an approach for the 
delivery of poorly water-soluble drugs from the 
osmotic systems, especially controlled-porosity 
osmotic pump tablets [4]. 
 
Advantages  
1.  The OPT can be so designed that delivery 
of its drug would follow zero order 
kinetics and thus better control over the 
drug’s  in vivo performance is possible. 
2. The drug release from the osmotically 
controlled drug delivery systems are 
independent of the gastric pH and 
hydrodynamic conditions, which is mainly 
attributed to the unique properties of the 
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3. The delivery rate of drug from these 
systems is highly predictable and can be 
programmed by modulating the terms. 
 
4. It is possible to attain better release rates 
than those obtained with conventional 
diffusion based drug delivery systems. 
5. Drug release from the OCODDSs exhibits 
significant in vitro-in vivo correlation 
[IVIVC] within specific limits [2]. 
Disadvantages  
1. Drug release from the osmotic systems is 
affected to some extent by the presence of 
food.  
2. Retrieval of therapy is not possible in the 
case of unexpected adverse events. 
Basic components required for controlled-
porosity osmotic pump 
 
a) Drug 
b) Osmotic agent 
c) Semipermeable membrane    
d) Channeling agents or pore forming agents. 
a. Criteria for selection of a drug:  
 
 Short biological Half-life (2- 6 hrs)   
 High potency 
 Required for prolonged treatment        
(e.g: Nifedipine, Glipizide, Verapamil  
and Chlorpromazine hydrochloride). 
 
Vyas.P. et al (2004) developed an oral 
osmotic system which can deliver theophylline and 
salbutamol sulphate simultaneously for extended 
period of time and characterized it. An optimized 
system was selected to study the effect of 
concentration of pore forming agents and orifice 
diameter on the release of the drugs. The release 
profiles of both drugs were satisfactory when 
compared with marketed controlled release 
formulations [3]. 
 
Roger A. Rajewski et al (2004) 
investigated the application of controlled-porosity 
osmotic pump tablet (OPT) utilizing (SBE)7m - -CD 
both as a solubilizer and an osmotic agent for drugs 
with varying physical properties. OPTs utilizing 
(SBE)7m - -CD were prepared for five poorly 
soluble drugs such as  prednisolone, estradiol, 
naproxen, indomethacine and chlorpromazine and 
for two highly water soluble drugs such as diltiazem 
hydrochloride and salbutamol sulfate. It was found 
that for the soluble drugs (SBE)7m - -CD acts 
primarily as an osmotic and an OPT control agent. 
Significantly, (SBE)7m - -CD not only enhances the 
delivery of poorly soluble drugs from OPTs but acts 
as a controlling excipient for soluble drugs such that 
the release rate, corrected for tablet surface area, of 
both poorly soluble and soluble drugs are similar 
[4].   
 
Roger A. Rajewski et al (1999) studied 
the membrane controlling factors responsible for 
drug release from a controlled-porosity osmotic 
pump tablet (OPT) that utilizes  sulfobutyl ether- -
cyclodextrin, (SBE)7m - -CD,  both as solubilizing 
agent and osmotic agent. The release rate of 
chlorpromazine (CLP) from OPTs containing 
(SBE)7m - -CD increased with increasing amounts 
of micronized lactose and decreasing amounts of 
triethyl citrate. The effect of lactose particle size in 
the membrane on drug release was studied [5].  
 
b. Osmotic agent 
 
Polymeric osmogents are mainly used in 
the fabrication of osmotically controlled drug 
delivery systems and other modified devices for 
controlled release of relatively insoluble drugs. 
Osmotic pressures for concentrated solution of 
soluble solutes commonly used in controlled release 
formulations are extremely high, ranging from 30 
atm for sodium phosphate up to 500 atm for a 
lactose-fructose mixture (table 2). These osmotic 
pressures can produce high water flows across 
semipermeable membranes [3]. The osmotic water 
flow across a membrane is given by the equation,     






Where dv/dt, is the rate of water flow across the 
membrane of area A, thickness l, permeability  in 









Stella J. et al (1999) developed controlled-
porosity osmotic pump system for poorly water-
soluble drugs such as testosterone using sulfobutyl 
ether -cyclodextrin (SBE)7m- -CD sodium salt, 
which can act as both a solublizing agent and an 
osmotic agent. The effect of (SBE)7m-β-CD as the 
solubilizing and osmotic pump agent was compared 
with hydroxypropyl-β-cyclodextrin (HP-β-CD), a 
  A     
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neutral cyclodextrin, and a sugar mixture (osmotic 
agent only). Testosterone release from the device 
was significantly faster with (SBE)7m-β-CD than 
with HP-β-CD or the sugar mixture. It was 
concluded that (SBE)7m- -CD provides novel 
properties for the development of controlled 





Table 3. Specifications for controlled- porosity osmotic pump [15] 
        Materials Specifications 
Plasticizers and flux 
Regulating agents 










1 to 1000, preferably 20 to 500 m 
 
Microporous nature 
Pore forming additives 
 
5 to 95% pores between 10a to 100 m diameter 
0.1 to 60%, preferably 0.1 to 50%, by weight, based on the total weight of 
additive and polymer 
 
 




Core loading (size) 
0.05 mg to 5 g or more (include dosage forms for  
Humans and animals) 
Osmotic pressure    
developed by a solution of    
core 





To get continuous, uniform release of 90% or greater of the initially loaded core 
mass solubility, S, to the core mass density, , that is S/ , must be 0.1 or lower. 
Typically it occurs when 10% of the initially loaded core mass saturates a volume 
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c. Semipermeable Membrane  
 
The membrane should be stable to both 
outside and inside environments of the device. The 
membrane must be sufficiently rigid so as to retain 
its dimensional integrity during the operational 
lifetime of the device. The membrane should also be 
relatively impermeable to the contents of dispenser 
so that osmogent is not lost by diffusion across the 
membrane. Finally, the membrane must be 
biocompatible. Some good examples for polymeric 
materials that form membranes are cellulose esters 
like cellulose acetate, cellulose acetate butyrate, 
cellulose triacetate, ethyl cellulose and Eudragits 
[8].  
 
Ideal properties of semipermeable membrane [9] 
 
The semipermeable membrane must meet some 
performance criteria, 
a) The material must possess sufficient wet 
strength (10-5 Psi) and wet modules so 
(10-5 Psi) as to retain its dimensional 
integrity during the operational lifetime of 
the device. 
b) The membrane must exhibit sufficient 
water permeability so as to attain water 
flux rates (dv/dt) in the desired range. The 
water vapour transmission rates can be 
used to estimate water flux rates. 
c) The reflection coefficient ( ) or 
“leakiness” of the osmotic agents should 
approach the limiting value of unity. But 
polymer membranes must be more 
permeable to water. 
 
Hai Bang Lee et al (2000) studied the 
sandwiched osmotic tablet system (SOTS). A 
sandwiched osmotic tablet core surrounded by a 
cellulose acetate membrane with two orifices on the 
surfaces of both sides was successfully prepared for 
the purpose of delivering nifedipine. The 
appropriate orifice size was observed in the range of 
0.50 – 1.41 mm. It was also found that the drug 
release rate of SOTS could be increased by 
incorporating hydrophilic plasticizer in the 
membrane, whereas it could be decreased by 
incorporating a hydrophobic plasticizer [8]. 
 
Toshiaki Nagakura et al (1996) designed 
an osmotic pump using a semipermeable membrane 
that changes its volume according to the 
concentration of the outside solution. By a 
mechanochemical actuator mechanism, an insulin 
pump works by changing the glucose concentration.  
It was found that this pump may possibly be used in 
the treatment of diabetes mellitus patients [10]. 
 
Herbig S. M.  et al (1995) found a new 
type of asymmetric membrane tablet coatings 
offering significant advantages over conventional 
osmotic tablets. These asymmetric-membrane 
coatings can be used to make osmotic drug-delivery 
formulations with several unique characteristics. 
The permeability of the coating to water can be 
adjusted by controlling the membrane structure, 
thereby allowing the control of the release kinetics 
without altering the coating material or significantly 
varying its concentration. The use of asymmetric-
membrane coatings on pharmaceutical tablets is 
described in this study; the coatings have also been 
applied to capsules and multi-particulate 
formulations [11]. 
 
d. Channeling agents/ leachable pore forming 
agents 
 
These are the water-soluble components 
which play an important role in the controlled drug 
delivery systems. When the dissolution medium 
comes into contact with the semipermeable 
membrane it dissolves the channeling agent and 
forms pores on the semipermeable barrier. Then the 
dissolution fluid enters the osmotic system and 
releases the drug in a controlled manner over a long 
period of time by the process of osmosis. Some 
examples of channeling agents are polyethylene 
glycol (PEG) 1450, -mannitol, bovine serum 
albumin (BSA), diethylphthalate, dibutylphthalate 
and sorbitol [12, 13, 14]. 
Mahalaxmi.R et al (2009) developed the 
extended release controlled porosity osmotic pump 
formulations of model drug glipizide using a 
wicking agent and a solubilizing agent. The effect of 
different formulation variables like level of wicking 
agent, solubilizing agent, level of pore former and 
membrane weight gain on in vitro release were 
studied. Drug release was found to be affected by 
the level of wicking agent and solubilizing agent in 
the core. Glipizide release from controlled porosity 
osmotic pump was directly proportional to the level 
of pore former (sorbitol) and inversely proportional 
to membrane weight gain [12].  
 
Pradeep Vavia. R et al (2003) designed a 
controlled porosity osmotic pump based on 
controlled release systems of pseudoephedrine in 
which cellulose acetate was used as a 
semipermeable membrane. The effect of pH on drug 
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release was also studied.  This system was found to 
deliver pseudoephedrine at a zero order rate for 
twelve (12) hrs independent of the environmental 
pH [13]. 
 
Ji-Eon Kim et al (2000) studied the effect 
of various pore formers on the controlled release of 
an antibacterial agent from a polymeric device. 
Cefadroxil was chosen as the model antibiotic and 
was incorporated into a polyurethane matrix by the 
solvent-casting method. Polyethylene glycol 1450 
or -mannitol, or bovine serum albumin (BSA) 
was used as a pore former. The morphological 
changes in the matrices before and after release 
studies were investigated by scanning electron 
microscopy (SEM). Changing the weight fraction 
and particle size of the pore formers/drug mixtures 
could control the release of cefadroxil from the 
matrix. The release rate of cefadroxil increased as 
the loading dose of the pore former increased 
(15<20<25%) [14]. 
 
Gaylen Z M. et al (1985) studied zero-
order release of water-soluble osmotically active 
agents from tablets coated with controlled-porosity 
walls. The walls were sponge like in appearance and 
substantially permeable to both water and dissolved 
solutes. The rate of release was a function of the 
wall thickness and the level of leachable pore 
forming agents. Release was insensitive to the pH 
and degree of agitation in the receptor media. The 
concept of osmotically actuated drug delivery on an 
equivalent mass per unit surface area basis was 
demonstrated [15]. 
 
Rajan K. Verma et al (2002) studied the 
formulation aspects in the development of 
osmotically controlled oral drug delivery systems. 
In this review, different types of oral osmotic 
systems, various factors governing drug release 
from these systems and critical formulation factors 
were discussed [16]. 
 
Gaylen. M et al (1991) studied the 
application of either solubility or resin-modulated 
method to effectively manipulate drug release 
kinetics from controlled porosity osmotic pumps. 
These solubility-modulated devices administered to 
dogs release diltiazem hydrochloride with similar in 
vivo / in vitro kinetics. These approaches may be 
applicable to extend osmotic pump technology to 
drugs with intrinsic water solubility that is too high 
or low for conventional osmotic pump formulation 
[17]. 
 
Sanjay Garg et al (2003) studied the 
development and evaluation of extended release 
formulations of isosorbide mono nitrate (IMN) 
based on osmotic technology. The release from 
developed formulations was independent of pH and 
agitational intensity, but dependent on the osmotic 
pressure of the release media. Results of SEM 
studies showed the formation of pores in the 
membrane from where the drug release occurred. 
Prediction of steady state levels, showed the plasma 
concentrations of IMN to be within the desired 
range [18]. 
 
Andrew Tasker et al (2000) studied the 
use of osmotic mini pumps as alternatives for 
injections for sustained drug delivery in adult rats. 
Sustained delivery rat pumps were assigned to 
control, mini-pump or sham surgery treatment. 
Based on the results the use of osmotic mini-pumps 
is a viable alternative to repeated injections for 
sustained delivery [19]. 
AK Philip et al (2008) developed an asymmetric 
membrane capsular system, formed in situ, for 
poorly water soluble drug, ketoprofen and evaluated 
it by both in vitro and in vivo methods for osmotic 
and controlled release of the drug. Membrane 
characterization by scanning electron microscopy 
showed an outer dense region with less pores and an 
inner porous region for the prepared asymmetric 
membrane [20]. 
 
Longxiao Liu et al (2008) developed the 
bilayer-core osmotic pump tablet (OPT) for 
nifedipine which does not require laser drilling to 
form the drug delivery orifice. The bilayer-core 
consisted of two layers: (a) push layer and (b) drug 
layer, and was made with a modified upper tablet 
punch, which produced an indentation at the center 
of the drug layer surface. The indented tablets were 
coated by using a conventional pan-coating process. 
Sodium chloride was used as osmotic agent, 
polyvinylpyrrolidone as suspending agent and 
croscarmellose sodium as expanding agent. The 
indented core tablet was coated by ethyl cellulose as 
semipermeable membrane containing polyethylene 
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CONTROLLED POROSITY OSMOTIC PUMP* 
 
 




Microporous semipermeable laminated osmotic system 
 
 
Osmotic system having laminated wall comprising of semipermeable 
lamina and microporous lamina 
 
 
Semipermeable membrane consisting of impregnated microporous 
membrane 
 
Semipermeable membrane consisting of a microporous film 
impregnated with a hydrophilic polymer 
 
 
Controlled-porosity solubility modulated osmotic pump for delivering 
of drug having low water solubility* 
 
 
Controlled-porosity solubility modulated osmotic pump for delivering 
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Table 6. Marketed products of different osmotic systems 
 
Product Name  Active  Design  Dose  
Acutrim  Phenylpropanolamine  Elementary pump  75 mg  
Alpress LP  Prazosin  Push -Pull  2.5 - 5 mg  
Cardura XL  Doxazosin  Push -Pull  4, 8 mg  
Covera HS  Verapamil  Push -Pull with time delay  180, 240 mg  
Ditropan XL  Oxybutinin chloride  Push -Pull  5, 10 mg  
Dynacirc CR  Isradipine  Push -Pull  5, 10 mg  
Efidac 24  Pseudoephiderine  Elementary Pump  60 mg IR, 180 mg CR  
Efidac 24  Chlorpheniramine meleate  Elementary Pump  4 mg IR, 12 mg CR  
Glucotrol XL  Glipizide  Push - Pull  5, 10 mg  
 
 
permeability. The in- vitro drug release 
profiles of various formulations were evaluated by 
similarity factor (f2). It was found that the optimal 
OPT was able to deliver nifedipine by an 
approximately zero-order process up to 24 h, 
independent of both release media and agitation 
rates[21]. Different types of osmotic systems-
design, mechanism and uses and the specifications 
for the core of controlled porosity osmotic pump 
tablet and various marketed products of different 






It can be concluded that the oral 
controlled-porosity osmotic pump system 
comprising a monolithic tablet coated with a 
semipermeable membrane containing different 
levels of pore forming agents can be developed for 
poorly water soluble drugs. These osmotic devices 
could be designed and optimized to deliver poorly 
soluble drugs at a controlled rate for extended 
periods of time by changing the drug: osmogent 
ratio, type of channeling agent and its concentration. 
The rate of release may be controlled through: 1) the 
level of pore formers incorporated into the wall; 2) 
the nature of the insoluble polymer component of 
the wall; 3) the thickness of the surface of the wall; 
4) total solubility and osmotic pressure of the core; 
and 5) the drug load in the core.  The osmotic 
system may be used to deliver drugs at a controlled 
rate over a period of 12 hours. This system is simple 
to prepare with no drilling required and hence it can 
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